Actym Therapeutics’ proprietary STACT™ biological platform is highly modular, multi-faceted and enables cell-, microenvironment-, and tissue-targeted delivery of large, multiplexed plasmid payloads via systemic administration. Expression of payloads, including therapeutic RNA, protein, peptide, and gene editing effectors, can be enabled in either the bacterial vehicle or targeted human cells. Additionally, its engineered auxotrophy allows for […]
Category: rna therapeutics
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors | The Manila Times
This press release contains express and implied forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Entrada’s strategy, future operations, prospects and plans, objectives of management, the validation and differentiation of Entrada’s approach and EEV platform and its ability to […]
Actym Therapeutics’ STACT™ Platform for RNA Therapeutics
In a groundbreaking development, Actym Therapeutics has secured US patents for their innovative STACT™ biological platform. This platform offers a versatile approach to delivering large, multiplexed plasmid payloads to specific cells, microenvironments, and tissues via systemic administration. By leveraging this technology, Actym can facilitate the expression of various therapeutic agents, such as RNA, proteins, peptides, […]
